The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.68 in the last session, up 1.20% from day before closing price of $1.66. In other words, the price has increased by $1.20 from its previous closing price. On the day, 0.33 million shares were traded. LCTX stock price reached its highest trading level at $1.69 during the session, while it also had its lowest trading level at $1.63.
Ratios:
We take a closer look at LCTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 386950240 and an Enterprise Value of 347841248. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.76 while its Price-to-Book (P/B) ratio in mrq is 17.56. Its current Enterprise Value per Revenue stands at 32.16 whereas that against EBITDA is -17.678.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.75, which has changed by 2.254902 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -3.43%, while the 200-Day Moving Average is calculated to be 50.15%.
Shares Statistics:
According to the various share statistics, LCTX traded on average about 1.90M shares per day over the past 3-months and 1448270 shares per day over the past 10 days. A total of 230.33M shares are outstanding, with a floating share count of 217.62M. Insiders hold about 5.52% of the company’s shares, while institutions hold 44.98% stake in the company. Shares short for LCTX as of 1764288000 were 22837063 with a Short Ratio of 12.49, compared to 1761868800 on 33795581. Therefore, it implies a Short% of Shares Outstanding of 22837063 and a Short% of Float of 17.580000000000002.
Earnings Estimates
. The current market rating for Lineage Cell Therapeutics Inc (LCTX) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.0 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.14 and -$0.42 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.06, with 6.0 analysts recommending between $0.03 and -$0.12.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $1.96M. It ranges from a high estimate of $3.68M to a low estimate of -$1.75M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $2.87M
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $11.63M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $9.9M. In the same quarter a year ago, actual revenue was $9.5M
